Applying Spectral Shift technology to study IDPs: Direct binding and displacement assays of MYC:MAX inhibitors

December 15, 2023

MYC is an important therapeutic target that associates with MAX to regulate gene transcription. Its lack of binding pockets and the presence of disordered regions make it a difficult protein to study with biophysical tools that require immobilization during drug discovery and development.

For this case study we used Dianthus with Spectral Shift technology to evaluate the direct binding of three MYC:MAX inhibitors, and their ability to displace DNA. The immobilization-free, in-solution, and fluorescence-based method made it possible to easily study interactions involving a protein with intrinsically disordered regions like MYC.

Previous Article
Direct comparison of binding affinities from Spectral Shift and SPR for biotinylated targets
Direct comparison of binding affinities from Spectral Shift and SPR for biotinylated targets

Up next
Selective degradation of cancer target WDR5 — Evaluation of PROTACs binary and ternary affinities with Spectral Shift
Selective degradation of cancer target WDR5 — Evaluation of PROTACs binary and ternary affinities with Spectral Shift

Chances are your company’s research and development pipeline includes several PROTAC candidates — placing y...

Ready to tackle your challenging affinity screening?

Discover tools you can use

Learn more